Genomics of Drug Sensitivity in Cancer
Cell Line: MDA-MB-468
Link to Cell Model Passport
Drug | Targets | Z score |
|---|---|---|
| Sinularin | -3.13288 | |
| 667880 | -2.84407 | |
| 743380 | -2.632 | |
| Acetalax | -2.43856 | |
| 741909 | -2.35433 | |
| TAF1_5496 | TAF1 | -2.33497 |
| Ulixertinib | ERK1, ERK2 | -2.29151 |
| Dihydrorotenone | -2.20552 | |
| Acetalax | -2.1681 | |
| 123829 | -2.11291 | |
| OF-1 | BRPF1B, BRPF2 | -1.97804 |
| LMB_AB3 | PPP1R15B | -1.89768 |
| Leflunomide | Pyrimidine synthesis inhibitor | -1.79552 |
| Avagacestat | Amyloid beta20, Amyloid beta40 | -1.72249 |
| Wnt-C59 | PORCN | -1.64386 |
| N27922-53-1 | -1.58661 | |
| alpha-lipoic acid | Metabolism | -1.58506 |
| Dacarbazine | CP11A | -1.5642 |
| LGK974 | PORCN | -1.54579 |
| ML323 | USP1, UAF1 | -1.52658 |
| Eg5_9814 | KSP11 | -1.51382 |
| 5-azacytidine | DNA methyltransferases | -1.51008 |
| Mirin | MRE11 | -1.50293 |
| IGF1R_3801 | IGFR1 | -1.49628 |
| Alisertib | AURKA | -1.49232 |
The Genomics of Drug Sensitivity in Cancer Project is a collaboration
between the Cancer Genome Project
at the Wellcome Sanger Institute (UK)
and the Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center (USA). This work is funded by Wellcome.
at the Wellcome Sanger Institute (UK)
and the Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center (USA). This work is funded by Wellcome.
https://www.cancerrxgene.org/cellline/MDA-MB-468/908123
Contact us | Cookies policy | Terms & Conditions.
This site is hosted by the Wellcome Sanger Institute.